208 related articles for article (PubMed ID: 35723021)
1. Epidermal growth factor receptor activation confers resistance to lenvatinib in thyroid cancer cells.
Ohno K; Shibata T; Ito KI
Cancer Sci; 2022 Sep; 113(9):3193-3210. PubMed ID: 35723021
[TBL] [Abstract][Full Text] [Related]
2. EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells.
He X; Hikiba Y; Suzuki Y; Nakamori Y; Kanemaru Y; Sugimori M; Sato T; Nozaki A; Chuma M; Maeda S
Sci Rep; 2022 May; 12(1):8007. PubMed ID: 35568782
[TBL] [Abstract][Full Text] [Related]
3. Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance.
Khan HY; Ge J; Nagasaka M; Aboukameel A; Mpilla G; Muqbil I; Szlaczky M; Chaker M; Baloglu E; Landesman Y; Mohammad RM; Azmi AS; Sukari A
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905765
[TBL] [Abstract][Full Text] [Related]
4. SoLAT (Sorafenib Lenvatinib alternating treatment): a new treatment protocol with alternating Sorafenib and Lenvatinib for refractory thyroid Cancer.
Kim SY; Kim SM; Chang HJ; Kim BW; Lee YS; Park CS; Park KC; Chang HS
BMC Cancer; 2018 Oct; 18(1):956. PubMed ID: 30286728
[TBL] [Abstract][Full Text] [Related]
5. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
6. Sophoridine suppresses lenvatinib-resistant hepatocellular carcinoma growth by inhibiting RAS/MEK/ERK axis via decreasing VEGFR2 expression.
Zhao Z; Zhang D; Wu F; Tu J; Song J; Xu M; Ji J
J Cell Mol Med; 2021 Jan; 25(1):549-560. PubMed ID: 33210432
[TBL] [Abstract][Full Text] [Related]
7. EGFR activation limits the response of liver cancer to lenvatinib.
Jin H; Shi Y; Lv Y; Yuan S; Ramirez CFA; Lieftink C; Wang L; Wang S; Wang C; Dias MH; Jochems F; Yang Y; Bosma A; Hijmans EM; de Groot MHP; Vegna S; Cui D; Zhou Y; Ling J; Wang H; Guo Y; Zheng X; Isima N; Wu H; Sun C; Beijersbergen RL; Akkari L; Zhou W; Zhai B; Qin W; Bernards R
Nature; 2021 Jul; 595(7869):730-734. PubMed ID: 34290403
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of IRAK1/4 enhances the antitumor effect of lenvatinib in anaplastic thyroid cancer cells.
Kawamura Y; Saijo K; Imai H; Ishioka C
Cancer Sci; 2021 Nov; 112(11):4711-4721. PubMed ID: 34328666
[TBL] [Abstract][Full Text] [Related]
9. Characterization of Cisplatin Effects in Lenvatinib-resistant Hepatocellular Carcinoma Cells.
Hamaya S; Fujihara S; Iwama H; Fujita K; Shi T; Nakabayashi R; Mizuo T; Takuma K; Nakahara M; Oura K; Tadokoro T; Mimura S; Tani J; Morishita A; Kobara H; Ono M; Himoto T; Masaki T
Anticancer Res; 2022 Mar; 42(3):1263-1275. PubMed ID: 35220216
[TBL] [Abstract][Full Text] [Related]
10. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
Ferrari SM; Bocci G; Di Desidero T; Elia G; Ruffilli I; Ragusa F; Orlandi P; Paparo SR; Patrizio A; Piaggi S; La Motta C; Ulisse S; Baldini E; Materazzi G; Miccoli P; Antonelli A; Fallahi P
Oncol Rep; 2018 May; 39(5):2225-2234. PubMed ID: 29517103
[TBL] [Abstract][Full Text] [Related]
11. A novel heat shock protein inhibitor KU757 with efficacy in lenvatinib-resistant follicular thyroid cancer cells overcomes up-regulated glycolysis in drug-resistant cells in vitro.
Subramanian C; Gorney R; Wang T; Ge D; Zhang N; Zuo A; Blagg BSJ; Cohen MS
Surgery; 2021 Jan; 169(1):34-42. PubMed ID: 32718802
[TBL] [Abstract][Full Text] [Related]
12. Anti-cancer Effects of HNHA and Lenvatinib by the Suppression of EMT-Mediated Drug Resistance in Cancer Stem Cells.
Lee YS; Kim SM; Kim BW; Chang HJ; Kim SY; Park CS; Park KC; Chang HS
Neoplasia; 2018 Feb; 20(2):197-206. PubMed ID: 29331886
[TBL] [Abstract][Full Text] [Related]
13. Anti-PD-1/PD-L1 therapy augments lenvatinib's efficacy by favorably altering the immune microenvironment of murine anaplastic thyroid cancer.
Gunda V; Gigliotti B; Ashry T; Ndishabandi D; McCarthy M; Zhou Z; Amin S; Lee KE; Stork T; Wirth L; Freeman GJ; Alessandrini A; Parangi S
Int J Cancer; 2019 May; 144(9):2266-2278. PubMed ID: 30515783
[TBL] [Abstract][Full Text] [Related]
14. Lenvatinib in Advanced, Radioactive Iodine-Refractory, Differentiated Thyroid Carcinoma.
Yeung KT; Cohen EE
Clin Cancer Res; 2015 Dec; 21(24):5420-6. PubMed ID: 26487760
[TBL] [Abstract][Full Text] [Related]
15. Lenvatinib in combination with golvatinib overcomes hepatocyte growth factor pathway-induced resistance to vascular endothelial growth factor receptor inhibitor.
Nakagawa T; Matsushima T; Kawano S; Nakazawa Y; Kato Y; Adachi Y; Abe T; Semba T; Yokoi A; Matsui J; Tsuruoka A; Funahashi Y
Cancer Sci; 2014 Jun; 105(6):723-30. PubMed ID: 24689876
[TBL] [Abstract][Full Text] [Related]
16. Impact of lenvatinib on renal function: long-term analysis of differentiated thyroid cancer patients.
Masaki C; Sugino K; Kobayashi S; Hosoi Y; Ono R; Yamazaki H; Akaishi J; Hames KY; Tomoda C; Suzuki A; Matsuzu K; Ohkuwa K; Kitagawa W; Nagahama M; Ito K
BMC Cancer; 2021 Aug; 21(1):894. PubMed ID: 34353305
[TBL] [Abstract][Full Text] [Related]
17. Curcumin-Mediated Resistance to Lenvatinib via EGFR Signaling Pathway in Hepatocellular Carcinoma.
Miyazaki K; Morine Y; Xu C; Nakasu C; Wada Y; Teraoku H; Yamada S; Saito Y; Ikemoto T; Shimada M; Goel A
Cells; 2023 Feb; 12(4):. PubMed ID: 36831279
[TBL] [Abstract][Full Text] [Related]
18. Tyrosine kinase inhibitors rechallenge in solid tumors: a review of literature and a case description with lenvatinib in thyroid cancer.
Felicetti F; Nervo A; Piovesan A; Berardelli R; Marchisio F; Gallo M; Arvat E
Expert Rev Anticancer Ther; 2017 Dec; 17(12):1093-1098. PubMed ID: 28988510
[TBL] [Abstract][Full Text] [Related]
19. Lenvatinib: first global approval.
Scott LJ
Drugs; 2015 Apr; 75(5):553-60. PubMed ID: 25795101
[TBL] [Abstract][Full Text] [Related]
20. The action and resistance mechanisms of Lenvatinib in liver cancer.
Buttell A; Qiu W
Mol Carcinog; 2023 Dec; 62(12):1918-1934. PubMed ID: 37671815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
